These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 16006165

  • 1. Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria.
    Wang L, Gamez A, Sarkissian CN, Straub M, Patch MG, Han GW, Striepeke S, Fitzpatrick P, Scriver CR, Stevens RC.
    Mol Genet Metab; 2005; 86(1-2):134-40. PubMed ID: 16006165
    [Abstract] [Full Text] [Related]

  • 2. Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria.
    Gámez A, Sarkissian CN, Wang L, Kim W, Straub M, Patch MG, Chen L, Striepeke S, Fitzpatrick P, Lemontt JF, O'Neill C, Scriver CR, Stevens RC.
    Mol Ther; 2005 Jun; 11(6):986-9. PubMed ID: 15922970
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Formulation and PEGylation optimization of the therapeutic PEGylated phenylalanine ammonia lyase for the treatment of phenylketonuria.
    Bell SM, Wendt DJ, Zhang Y, Taylor TW, Long S, Tsuruda L, Zhao B, Laipis P, Fitzpatrick PA.
    PLoS One; 2017 Jun; 12(3):e0173269. PubMed ID: 28282402
    [Abstract] [Full Text] [Related]

  • 6. Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report.
    Safos S, Chang TM.
    Artif Cells Blood Substit Immobil Biotechnol; 1995 Jun; 23(6):681-92. PubMed ID: 8556141
    [Abstract] [Full Text] [Related]

  • 7. Phenylalanine ammonia-lyase modified with polyethylene glycol: potential therapeutic agent for phenylketonuria.
    Ikeda K, Schiltz E, Fujii T, Takahashi M, Mitsui K, Kodera Y, Matsushima A, Inada Y, Schulz GE, Nishimura H.
    Amino Acids; 2005 Nov; 29(3):283-7. PubMed ID: 15977040
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pah(enu2) mice.
    Rossi L, Pierigè F, Carducci C, Gabucci C, Pascucci T, Canonico B, Bell SM, Fitzpatrick PA, Leuzzi V, Magnani M.
    J Control Release; 2014 Nov 28; 194():37-44. PubMed ID: 25151978
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phenylalanine ammonia lyase (PAL): From discovery to enzyme substitution therapy for phenylketonuria.
    Levy HL, Sarkissian CN, Scriver CR.
    Mol Genet Metab; 2018 Aug 28; 124(4):223-229. PubMed ID: 29941359
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The essential tyrosine-containing loop conformation and the role of the C-terminal multi-helix region in eukaryotic phenylalanine ammonia-lyases.
    Pilbák S, Tomin A, Rétey J, Poppe L.
    FEBS J; 2006 Mar 28; 273(5):1004-19. PubMed ID: 16478474
    [Abstract] [Full Text] [Related]

  • 16. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase.
    Sarkissian CN, Shao Z, Blain F, Peevers R, Su H, Heft R, Chang TM, Scriver CR.
    Proc Natl Acad Sci U S A; 1999 Mar 02; 96(5):2339-44. PubMed ID: 10051643
    [Abstract] [Full Text] [Related]

  • 17. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria.
    Sarkissian CN, Gámez A, Wang L, Charbonneau M, Fitzpatrick P, Lemontt JF, Zhao B, Vellard M, Bell SM, Henschell C, Lambert A, Tsuruda L, Stevens RC, Scriver CR.
    Proc Natl Acad Sci U S A; 2008 Dec 30; 105(52):20894-9. PubMed ID: 19095795
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.
    Longo N, Zori R, Wasserstein MP, Vockley J, Burton BK, Decker C, Li M, Lau K, Jiang J, Larimore K, Thomas JA.
    Orphanet J Rare Dis; 2018 Jul 04; 13(1):108. PubMed ID: 29973227
    [Abstract] [Full Text] [Related]

  • 19. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).
    Thomas J, Levy H, Amato S, Vockley J, Zori R, Dimmock D, Harding CO, Bilder DA, Weng HH, Olbertz J, Merilainen M, Jiang J, Larimore K, Gupta S, Gu Z, Northrup H, PRISM investigators.
    Mol Genet Metab; 2018 May 04; 124(1):27-38. PubMed ID: 29653686
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.